PL3103453T3 - Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy - Google Patents
Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowyInfo
- Publication number
- PL3103453T3 PL3103453T3 PL15746276T PL15746276T PL3103453T3 PL 3103453 T3 PL3103453 T3 PL 3103453T3 PL 15746276 T PL15746276 T PL 15746276T PL 15746276 T PL15746276 T PL 15746276T PL 3103453 T3 PL3103453 T3 PL 3103453T3
- Authority
- PL
- Poland
- Prior art keywords
- active ingredient
- medicinal composition
- carboxamide compound
- heterocyclic carboxamide
- diamino heterocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| EP15746276.3A EP3103453B1 (en) | 2014-02-04 | 2015-02-03 | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3103453T3 true PL3103453T3 (pl) | 2020-06-29 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15746276T PL3103453T3 (pl) | 2014-02-04 | 2015-02-03 | Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (pl) |
| EP (1) | EP3103453B1 (pl) |
| JP (1) | JP6390626B2 (pl) |
| KR (1) | KR102322338B1 (pl) |
| CN (3) | CN116509866A (pl) |
| AU (1) | AU2015215578B2 (pl) |
| BR (1) | BR112016017897A8 (pl) |
| CA (1) | CA2938818C (pl) |
| CY (1) | CY1122968T1 (pl) |
| DK (1) | DK3103453T3 (pl) |
| EA (1) | EA033304B1 (pl) |
| ES (1) | ES2788390T3 (pl) |
| HR (1) | HRP20200662T1 (pl) |
| HU (1) | HUE049437T2 (pl) |
| IL (1) | IL247077B (pl) |
| LT (1) | LT3103453T (pl) |
| ME (1) | ME03775B (pl) |
| MX (1) | MX363543B (pl) |
| MY (1) | MY193536A (pl) |
| PH (1) | PH12016501527B1 (pl) |
| PL (1) | PL3103453T3 (pl) |
| PT (1) | PT3103453T (pl) |
| RS (1) | RS60150B1 (pl) |
| SG (1) | SG11201606413RA (pl) |
| SI (1) | SI3103453T1 (pl) |
| SM (1) | SMT202000214T1 (pl) |
| TW (1) | TWI655945B (pl) |
| UA (1) | UA120607C2 (pl) |
| WO (1) | WO2015119122A1 (pl) |
| ZA (1) | ZA201605379B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200662T1 (hr) * | 2014-02-04 | 2020-10-02 | Astellas Pharma Inc. | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak |
| EP3318259B1 (en) | 2015-07-03 | 2023-01-11 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
| ES2894691T3 (es) * | 2015-11-04 | 2022-02-15 | Astellas Pharma Inc | Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3231846A1 (en) * | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| TW202304908A (zh) * | 2021-04-14 | 2023-02-01 | 日商衛材R&D企管股份有限公司 | 四氫吡啶并嘧啶化合物 |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011511949A (ja) * | 2008-02-12 | 2011-04-14 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ |
| DK2262807T3 (en) | 2008-03-19 | 2015-11-30 | Chembridge Corp | NOVEL tyrosine kinase inhibitors |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| KR20140105765A (ko) * | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| ES2831374T3 (es) * | 2012-11-21 | 2021-06-08 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| HRP20200662T1 (hr) * | 2014-02-04 | 2020-10-02 | Astellas Pharma Inc. | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak |
| WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| EP3318259B1 (en) * | 2015-07-03 | 2023-01-11 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
-
2015
- 2015-02-03 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 SM SM20200214T patent/SMT202000214T1/it unknown
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja not_active Ceased
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt not_active Application Discontinuation
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active Active
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527B1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| IL244206A0 (en) | A pharmaceutical preparation containing a pyrimidine compound as an active ingredient | |
| ZA201605379B (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| IL253538B (en) | Heterocyclic compound and pharmaceutical compound containing it | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| IL248090B (en) | Solid pharmaceutical preparations containing biopterin derivatives and their uses | |
| ZA201804203B (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| IL304109A (en) | Pharmaceutical preparations containing spinamide | |
| IL243227B (en) | History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them | |
| PL3313370T3 (pl) | Okulistyczna kompozycja farmaceutyczna | |
| IL249010A0 (en) | A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| SG11201608845PA (en) | Cosmetic composition containing mentha haplocalyx as active ingredient | |
| IL252663A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient | |
| PT3558261T (pt) | Composições farmacêuticas compreendendo safinamida | |
| EP3120848A4 (en) | Therapeutic/preventive agent containing coumarin derivative as active ingredient | |
| IL252664A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient |